Plants have been used for the treatment of various disorders regardless of their safety and efficacy profiles. Previous studies indicated that approximately 80% of the global population relies on traditional medicine for their primary healthcare.^[@bibr1-2515690X19886276][@bibr2-2515690X19886276][@bibr3-2515690X19886276]--[@bibr4-2515690X19886276]^ Nevertheless, the use of traditional plants has been associated with the adulteration of valuable medicinal components, poor cultivation and collection procedures, lack of standardization during preparation, poor storage conditions, and incertitude among traditional medicine practitioners, ultimately affecting the process of drug development.^[@bibr5-2515690X19886276]^ Despite challenges, there is great demand for development of new antibacterial agents from traditional medicinal plants. Therefore, it is worthwhile to properly evaluate the safety and efficacy of medicinal plants that are being used in various traditional medical systems. The need for newer, more effective, less expensive, and safer agents has become a paramount issue for overcoming current challenges including antimicrobial resistance.

The antimicrobial activities of medicinal plants is based on their bioactive phytoconstituents called secondary metabolites including alkaloids, terpenoids, flavonoids, tannins, and glycosides, among others.^[@bibr6-2515690X19886276]^ The crude extracts of various medicinal plants such as *Rhamnus prinoides*, *Calpurnia aurea*, *Peterollobium stellatum*, *Datura stramonium*, *Croton macrostachyus*, and *Acokanthera schimperi* extracts have been tested and approved for their antimicrobial activity in previous studies.^[@bibr7-2515690X19886276][@bibr8-2515690X19886276][@bibr9-2515690X19886276]--[@bibr10-2515690X19886276]^ In addition, a study conducted by Abebe et al on the antibacterial activity of *Verbena officinalis* L was found inconclusive and very shallow.^[@bibr11-2515690X19886276]^ Moreover, there are still several medicinal plants such as *Melilotus elegans* that have been used traditionally for the treatment of infectious diseases indicating the need for further scientific studies to validate and develop safe and efficacious antibacterial agents.

The anti-inflammatory and analgesic effects of *V officinalis* extract in different formulations have been studied and confirmed.^[@bibr12-2515690X19886276]^ In addition, the extract of aerial parts of *V officinalis* has traditionally had antipyretic, sedative,^[@bibr13-2515690X19886276]^ and anticancer effects.^[@bibr14-2515690X19886276]^ Moreover, the plasters of aerial part of *V officinalis* are used as hemostatics and antirheumatics in knees and elbows.^[@bibr15-2515690X19886276]^ Apart from this, the extract or the juice of *V officinalis* has been used for the treatment of tonsillitis and ascariasis.^[@bibr16-2515690X19886276]^ The leaf extract is also used in the treatment of ear disease by applying some drops of the extract through the ear^[@bibr16-2515690X19886276]^ and for the control of snake bite poisoning.^[@bibr17-2515690X19886276]^ For instance, the extract of the whole plant, after boiling with tea, is given orally for the treatment of dysentery.^[@bibr18-2515690X19886276],[@bibr19-2515690X19886276]^

*Myrtus communis* L (family: Myrtaceae) is one of the most important drugs being used in the Unani system of phytomedicine since ancient Greece period. In Ethiopia, common myrtle or *M communis* has several vernacular names such as Ades (Amharic, Guragegna, Tigregna), Addisaa, coddoo (Afan Oromo), and wobattaa (Welaitigna).^[@bibr20-2515690X19886276],[@bibr21-2515690X19886276]^ It is a well-known shrub for its therapeutic, cosmetic, and food uses.^[@bibr22-2515690X19886276]^ Various parts of the plant have also been used as folkloric repute for the management of several disorders including hemorrhoid, inflammation, pulmonary diseases,^[@bibr23-2515690X19886276]^ and wound infections.^[@bibr24-2515690X19886276]^ Besides, the decoction of leaf powder has been used for the treatment of eczema and other skin diseases.^[@bibr25-2515690X19886276]^ Moreover, the leaves have been traditionally used for the treatment of diarrhea in different traditional medical systems.^[@bibr24-2515690X19886276],[@bibr26-2515690X19886276],[@bibr27-2515690X19886276]^ In addition, it has been used for the treatment of dandruff,^[@bibr28-2515690X19886276]^ scabies,^[@bibr18-2515690X19886276]^ and headache.^[@bibr29-2515690X19886276]^

The third medicinal plant selected for this study was *Melilotus elegans*, which is one of the medicinal plants belonging to the family leguminosae.^[@bibr30-2515690X19886276]^ In Ethiopia, it has a wide distribution, particularly in highlands where the altitude ranges between 1700 and 2800 m above sea level. The plant is known by its vernacular names including "Egug" and "Gugi" in Amharic and "Yemamberi" in Tigregna ([Figure 1](#fig1-2515690X19886276){ref-type="fig"}).^[@bibr31-2515690X19886276],[@bibr32-2515690X19886276]^ In folk medicine, the powdered leaves of *M elegans* are mixed with butter and applied topically against hemorrhoids and mouth and wound infections.^[@bibr32-2515690X19886276]^ The plant can also be taken orally for the management of bronchial asthma. In addition, the leaf of the plant is used in the treatment of various disorders (excavated sore, piles, and ulcers).^[@bibr33-2515690X19886276]^ The crude extract and its isolated flavonoids from the leaves of *M elegans* have been shown to have anti-inflammatory activity in carrageenan-induced paw edema in rodents model.^[@bibr32-2515690X19886276]^

![Photographs of medicinal plants: (A) *Verbena officinalis*, (B) *Myrtus communis*, and (C) *Melilotus elegans*.](10.1177_2515690X19886276-fig1){#fig1-2515690X19886276}

The slow rate of new antimicrobial development in the area of antimicrobial therapy has become a global issue because antimicrobial research and development are not attractive to venture capitalists leading to an investment rate of less than 5%. Conversely, the high rate of antimicrobial resistance makes the majority of available medications ineffective, leading to a post-antibiotic era. Thus, safe alternatives are sought. In particular, there is a need to intensify research into medicinal plants claimed to be effective in the management of infectious diseases. The alternative and complementary therapies being used in traditional medicine should be integrated into conventional medicine to ensure the safe and efficacious use of drugs. Therefore, there must be a real commitment in commencing preclinical studies based on the folkloric repute to provide a benchmark for further studies. Therefore, this study aimed to investigate the in vitro antibacterial activities of the aforementioned medicinal plants having folkloric repute in different traditional medical systems including Ethiopian traditional medicine.

Methods and Materials {#section1-2515690X19886276}
=====================

Collection of Plant Materials and Their Authentication {#section2-2515690X19886276}
------------------------------------------------------

The leaves of *V officinalis* were collected from Debre Markos town and its surrounding areas, which is 300 km to the northwest of the capital of Ethiopia, Addis Ababa, in November 2017. Likewise, the leaves of *M communis* and *M elegans* were collected from Mersa, North Wollo, which is 490 km away from Addis Ababa to the northeast in December 2017. The identification of the plant specimens was undertaken by a taxonomist at the National Herbarium, College of Natural and Computational Sciences, Addis Ababa University, where voucher specimens were deposited for future reference: MS002/2017, MS003/2017, and MS004/2017 for *V officinalis*, *M communis*, and *M elegans*, respectively.

Preparation and Extraction of Plant Materials {#section3-2515690X19886276}
---------------------------------------------

The leaves of the aforementioned plants were gently washed with tap water to remove dirt and soil. The leaves of the plants were manually cut into pieces and dried under shade for 2 weeks. The dried plant materials were ground into an appropriate coarse powder using mortar and pestle. Then, 150 g of coarsely powdered leaves of each plant material was separately macerated in 2 L Erlenmeyer flask with 400 mL 80% methanol for 3 days with frequent agitation using mini-orbital shaker at room temperature. The extracts were filtered through double-layered muslin cloth followed by Whatman No. 1 filter paper (Schleicher and Schuell Micro Science Gmbh, Germany). The marcs of leaf extracts of each plant material were re-macerated twice (3 days for each batch) with the same volume of fresh solvent to increase the actual yield of extraction. A similar filtration procedure was undertaken to obtain the final filtrates. The combined filtrates were concentrated to dryness using rotary evaporator (Buchi labortechnik AG, Switzerland). The remaining aqueous residues of each plant material were deep-frozen to form ice and lyophilized (Operan, Korea Vacuum Limited, Korea) to obtain the final dried extract. The percentage yields of the extracts were determined as follows:
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Finally, the dried extracts were stored frozen in air-tight container until the day of experimentation.

Preliminary Phytochemical Screening {#section4-2515690X19886276}
-----------------------------------

The presence of secondary metabolites such as alkaloids, flavonoids, saponins, tannins, terpenoids, glycosides, and steroids was evaluated in the crude extracts using standard testing methods.^[@bibr34-2515690X19886276][@bibr35-2515690X19886276]--[@bibr36-2515690X19886276]^

Standard Laboratory Strains {#section5-2515690X19886276}
---------------------------

Standard isolates of different bacteria strains: American Type Culture Collection (ATCC) including *Staphylococcus aureus* (ATCC 25923), *Escherichia coli* (ATCC 25922), *Salmonella typhi* (ATCC 13062), *Shigella flexneri* (ATCC 12022), *Pseudomonas aeruginosa* (ATCC 27853), and *Proteus mirabilis* (ATCC 29906) were obtained from the Ethiopian Public Health Institute (Addis Ababa, Ethiopia). The bacteria were purposely selected for evaluating the spectrum of activity and considering the folkloric repute of the experimental plants.

Inoculum Preparation and Standardization {#section6-2515690X19886276}
----------------------------------------

Nutrient agar was prepared following the manufacturer's preparation protocol. Then, standard bacterial isolates were inoculated and spread on the prepared agar using inoculating wire loop following aseptic condition in safety cabinet (Bioair Instruments, Eurolone Company, Italy) and incubated for 24 hours at 37°C. The bacterial turbidity of each bacterium was prepared and standardized following the Clinical and Laboratory Standard Institute guideline.^[@bibr37-2515690X19886276]^ Having prepared the nutrient broth in distilled water and autoclaved it (Astell Scientific Ltd, England), 3 to 5 well-isolated colonies of the same morphological type of each bacterium were peaked up by wire loop from fresh agar plates of bacterial culture and aseptically transferred into test tubes containing 5 mL of nutrient broth and incubated for about 6 hours. The turbidity of the inoculum tube was adjusted to the already prepared turbidity equivalent of 0.5 McFarland standard, which is assumed to contain a bacterial concentration of 1 × 10^8^ CFU/mL.

Antibacterial Activity Assay {#section7-2515690X19886276}
----------------------------

### Agar Well Diffusion {#section8-2515690X19886276}

The antibacterial agar well diffusion method was conducted by following the method described by previous studies.^[@bibr8-2515690X19886276][@bibr9-2515690X19886276]--[@bibr10-2515690X19886276],[@bibr38-2515690X19886276]^ Bacterial broth culture was prepared equivalent to 0.5 McFarland standard as described previously. An aliquot of inoculum of the respective bacterium was streaked on the sterile Muller Hinton agar plates (prepared according to the manufacturer's guideline) using a sterile cotton swab to ensure even coverage of the plates with each bacterium following incubation. Then, the plated media were allowed to dry at room temperature for 30 minutes. On each plate, equidistant wells (4 for gram-positive and 5 for gram-negative bacteria having 2 controls) were made with a 6 mm diameter sterilized cork borer.^[@bibr10-2515690X19886276]^ The labeled wells were filled with 100 μL of 100, 200, and 400 mg/mL of leaf extracts of each plant material for each bacterium corresponding to 10, 20, and 40 mg/well concentrations. Commercial antibiotic powders (primary standards) of amoxicillin and ciprofloxacin (Ethiopian Pharmaceutical Industry, Epharm) were used as standard drugs. To match the preparation of extract solutions, the concentration of 250 μg/mL (25 μg/well) and 200 μg/mL (20 μg/well) solutions were prepared using sterile water for amoxicillin and ciprofloxacin, respectively. The solvent for dissolving crude extracts was 25% dimethylsulfoxide in sterile water and was treated as a negative control. Then, the plates were allowed to stand on a laboratory bench for approximately 2 hours to permit prediffusion of the extract to agar medium at room temperature.^[@bibr8-2515690X19886276],[@bibr39-2515690X19886276]^ Finally, the plates were incubated at 37°C for 24 hours. The resulting diameters of zones of inhibition, including the diameter of the well, were measured using a ruler and reported in millimeter. To maintain the consistency of measurements, each zone of inhibition was measured twice (one vertical and one horizontal measurement) and the average value was taken. The experiment was performed in triplicate for each bacterium and plant material and the mean zone of inhibition was calculated for each crude extract and standard antibiotics.

### Determination of the Minimum Inhibitory Concentration (MIC) {#section9-2515690X19886276}

The extracts having antibacterial activity in agar well diffusion technique were further processed for the quantitative determination of MIC values using serial broth dilution technique. In this method, the first test tube contained stock solutions (100 mg/mL) of each extract for each bacterium. The stock solutions were subjected to serial dilution with nutrient broth with final concentration being 0.032 mg/mL (100, 20, 4, 0.80, 0.16, and 0.032 mg/mL). Standardized microbial suspension of 1 mL was added to each test tube. The last 2 columns were reserved for positive (growth) and negative (sterility) controls. Control I which served as negative control, contained nutrient broth with extract in serial dilutions in the absence of bacterium, whereas control II was regarded as positive control and contained nutrient broth with respective bacterium and without extracts for comparing the turbidity status. The tubes were incubated at 37°C for 24 hours. In a series of test tubes, the lowest concentration of extracts at which no turbidity (growth) occurred was considered as the MIC cutoff point. All the procedures were performed in 3 independent tests, and the average value was taken as a final MIC value.

### Determination of Minimum Bactericidal Concentration (MBC) {#section10-2515690X19886276}

The determination of MBC values was performed in accordance with previous studies.^[@bibr8-2515690X19886276],[@bibr40-2515690X19886276]^ In line with the MIC experiment conducted in triplicate, the contents of test tubes above or equal to MIC cutoff points were subjected for aseptic subculturing in Muller Hinton agar free of antimicrobial disks and incubated at 37°C for 24 hours. Following incubation, the lowest concentration of the extract at which no bacterial growth occurred on agar plates was treated as the MBC cutoff point.

Data Analysis {#section11-2515690X19886276}
-------------

Data were entered and analyzed using IBM Statistical Package for the Social Sciences (SPSS) Version 20.0 software (Armonk, NY). Results were expressed as mean ± standard error of the mean (M ± SEM). The normality of the data distribution was checked using Kolmogorov-Smirnov and Shapiro-Wilk tests. For analyzing zone of inhibition, One-way analysis of variance was performed followed by Tukey's post-hoc test for multiple comparisons. MIC and MBC values were computed using descriptive statistics. The analysis was performed at 95% confidence level and *P* value \<.05 denoted statistical significant.

Results {#section12-2515690X19886276}
=======

Extraction Yields {#section13-2515690X19886276}
-----------------

The percentage yields of the 80% methanol leaf extracts of *V officinalis* (Vo-80ME), *M communis* (Mc-80ME), and *M elegans* (Me-80ME) were found to be 9.25% (w/w), 16.33% (w/w), and 10.60% (w/w), respectively.

Phytochemical Screening {#section14-2515690X19886276}
-----------------------

The preliminary phytochemical screening revealed that *M communis* was found rich in tested secondary metabolites except alkaloids. Only flavonoids and terpenoids were detected in the leaves of *V officinalis*. The leaves of *M elegans* are rich in flavonoids and saponins. Generally, the study indicated that flavonoids are common secondary metabolites in all extracts ([Table 1](#table1-2515690X19886276){ref-type="table"}).

###### 

Preliminary Phytochemical Screening of 80ME of the Leaves of *Verbena officinalis*, *Myrtus communis*, and *Melilotus elegans*

![](10.1177_2515690X19886276-table1)

  Constituents         *V officinalis*   *M communis*   *M elegans*
  -------------------- ----------------- -------------- -------------
  Cardiac glycosides   −                 \+             −
  Flavonoids           \+                \+             \+
  Alkaloids            −                 −              −
  Saponins             −                 \+             \+
  Steroids             −                 \+             −
  Tannins              −                 \+             −
  Terpenoids           \+                \+             −

Abbreviations: +, present; −, absent.

Antibacterial Activity {#section15-2515690X19886276}
----------------------

Both Vo-80ME and Mc-80ME showed remarkable zone of inhibitions against *S aureus* in a concentration-dependent manner. With similar concentrations across the extracts, Mc-80ME had the highest zone of inhibitions at all concentrations tested against this bacterium. However, Me-80ME did not have any inhibition at all tested concentrations indicating the absence of antibacterial activity ([Table 2](#table2-2515690X19886276){ref-type="table"}).

###### 

Zone of Inhibition (mm) of the Hydromethanolic Extracts of the Leaves of *Verbena officinalis*, *Myrtus communis*, and *Melilotus elegans* Against *Staphylococcus aureus*.\*

![](10.1177_2515690X19886276-table2)

  Dose               Zone of Inhibition (mm) Against *S aureus*                                 
  ------------------ -------------------------------------------- ----------------------------- --------------
  10 mg/well         11.33 ± 0.83^a\*\*^                          21.83 ± 0.44^a\*\*c\*d\*\*^   NA
  20 mg/well         14.83 ± 1.01^a\*\*^                          25.5 ± 0.76^a\*\*^            NA
  40 mg/well         18.67 ± 1.20^a\*\*^                          26.16 ± 0.60^a\*\*^           NA
  20 μg/well (CIP)   30.50 ± 2.78                                 31.50 ± 0.87                  30.67 ± 1.01

Abbreviations: CIP, ciprofloxacin; NA, no activity/inhibition at dose(s) tested.

\* Values are expressed as mean ± SEM (n = 3), analysis was performed with one-way analysis of variance followed by Tukey post hoc test: ^a^compared positive control (CIP), ^b^compared to 10 mg/well, ^c^compared to 20 mg/well, ^d^compared to 40 mg/well

\*\**P* \< .01; \**P* \< .05.

Besides, Vo-80ME was endowed with appreciable antibacterial activity against *E coli* and *S typhi* at lower and middle concentrations. Likewise, at 40 mg/well dose of Vo-80ME, the most susceptible strain was *E coli* with the zone of inhibition being 20.33 mm. The antibacterial activity of *V officinalis* against *P aeruginosa* was found very modest with the maximum zone of inhibition being 6.67 mm at the concentration of 40 mg/well. The leaf extract of *V officinalis* has also shown a relatively better antibacterial activity against *P mirabilis* than that of *S flexineri*. The leaf extract of *M elegans* (Me-80ME) exhibited a notable zone of inhibition against *E coli* at all tested concentrations in a concentration-dependent manner. This plant material was, however, devoid of any antibacterial activity against the 2 gram-negative aerobic bacilli, *P aeruginosa* and *P mirabilis*. Moreover, the antibacterial activity of the leaf of this plant material against *S typhi* and *S flexneri* was found extremely limited. The leaf extract of *M communis* showed remarkable antibacterial activities against all strains. Most important, the difficult to treat gram-negative bacterium *P aeruginosa* has shown the highest level of susceptibility to this plant material. Besides, Mc-80ME showed the highest zone of inhibition against *S flexneri*, with the maximum value being 26.17 mm corresponding to 40 mg/well concentration ([Table 3](#table3-2515690X19886276){ref-type="table"}).

###### 

Zone of Inhibition (mm) of the Hydromethanolic Extracts of the Leaves of *Verbena officinalis*, *Myrtus communis*, and *Melilotus elegans* Against Gram-Negative Bacteria\*.

![](10.1177_2515690X19886276-table3)

  Plant Material    Dose                Zone of Inhibition (mm)                                                                                                      
  ----------------- ------------------- --------------------------- ------------------------------- ------------------------------ --------------------------------- -----------------------------
  *V officinalis*   10 mg/well          12.00 ± 0.578^a\*\*e\*\*^   12.67 ± 1.45^a\*^               3.33 ± 0.88^a\*\*b\*\*e\*\*^   NA                                8.67 ± 2.03^a\*\*b\*\*^
                    20 mg/well          14.67 ± 1.45^a\*\*e\*\*^    15.00 ± 2.08                    8.66 ± 0.88^a\*\*b\*\*^        4.50 ± 0.29^a\*\*^                13.33 ± 1.45^a\*\*b\*\*^
                    40 mg/well          20.33 ± 0.88^a\*\*b\*\*^    16.50 ± 0.28                    13.00 ± 0.58^a\*\*^            6.67 ± 0.88^a\*\*^                16.00 ± 1.04^a\*\*b\*\*^
                    25 μg/well (AMOX)   13.83 ± 0.33^a\*\*^         20.33 ± 2.18                    18.67 ± 2.96^a\*\*^            NT                                27.67 ± 2.40
                    20 μg/well (CIP)    30.67 ± 0.93                24.17 ± 3.08                    32.67 ± 0.33                   18.67 ± 1.76                      31.67 ± 0.44
  *M communis*      10 mg/well          13.33 ± 0.33^a\*\*e\*^      13.33 ± 0.33^a\*\*b\*\*e\*\*^   20.83 ± 0.93^a\*\*e\*\*^       14.83 ± 0.44^a\*\*\ d\*\*e\*\*^   12.17 ± 0.73^a\*\*b\*\*e\*^
                    20 mg/well          16.83 ± 1.87^a\*\*^         15.83 ± 0.93^a\*\*b\*\*e\*^     23.83 ± 0.93^a\*\*^            20.50 ± 0.50                      14.50 ± 1.15^a\*\*b\*\*^
                    40 mg/well          19.16 ± 0.44^a\*\*b\*^      18.50 ± 0.50^a\*\*^             26.17 ± 1.20^a\*\*b\*\*^       22.83 ± 0.93^a\*^                 19.33 ± 1.45^a\*\*b\*\*^
                    25 μg/well (AMOX)   12.16 ± 0.44^a\*\*^         20.50 ± 0.289                   20.00 ± 0.58^a\*\*^            NT                                26.83 ± 1.59
                    20 μg/well (CIP)    31.67 ± 1.67                22.17 ± 0.44                    34.83 ± 0.44                   19.50 ± 0.29                      31.00 ± 0.58
  *M elegans*       10 mg/well          11.33 ± 0.33^a\*\*\*^       0.67 ± 0.33^a\*\*b\*\*^         1.50 ± 0.29^a\*\*\*b\*\*\*^    NA                                NA
                    20 mg/well          17.67 ± 2.40^a\*\*\*^       1.17 ± 0.17^a\*\*b\*\*^         3.33 ± 0.60^a\*\*\*b\*\*\*^    NA                                NA
                    40 mg/well          19.50 ± 1.26^a\*\*b\*^      2.00 ± 0.29^a\*\*b\*\*^         5.00 ± 0.58^a\*\*\*b\*\*\*^    NA                                NA
                    25 μg/well (AMOX)   11.33 ± 0.33^a\*\*\*^       19.50 ± 1.80                    20.67 ± 0.33^a\*\*\*^          NT                                25.67 ± 1.45
                    20 μg/well (CIP)    32.00 ± 2.00                20.67 ± 0.67                    34.83 ± 1.64                   19.33 ± 0.33                      31.33 ± 1.45

Abbreviations: AMOX, amoxicillin; CIP, ciprofloxacin; NA, no activity/inhibition at dose(s) tested; NT, not tested for controls.

\* Values are expressed as mean ± SEM (n = 3); analysis was performed with one-way analysis of variance followed by Tukey's post hoc test: ^a^compared with positive control (ciprofloxacin), ^b^compared with positive control (amoxicillin), ^c^compared with 10 mg/well, ^d^compared with 20 mg/well, ^e^compared with 40 mg/well.

\**P* \< .05; \*\**P* \< .01; \*\*\**P* \< .001.

MIC of the Leaf Extracts {#section16-2515690X19886276}
------------------------

To quantitatively investigate the antibacterial activity, the MIC cutoff points were determined for each plant extract. Accordingly, lower MICs were recorded against *S typhi* (0.16 mg/mL) and *E coli* (0.8 mg/mL) in Vo-80ME. In Mc-80ME, the lowest MIC cutoff point was observed against *S typhi* (0.032 mg/mL). However, in Me-80ME, relatively higher MIC values were recorded with the lowest value being 4.00 mg/mL against *E coli* ([Table 4](#table4-2515690X19886276){ref-type="table"}).

###### 

MIC (in mg/mL) of Hydromethanolic Extracts Using Broth Dilution Techniques (Prepared From 100 mg/mL Stock Solution).

![](10.1177_2515690X19886276-table4)

  Bacteria                   Plant Materials                  
  -------------------------- ----------------- -------------- --------------
  *Staphylococcus aureus*    4.00 ± 0.00       0.80 ± 0.00    ---
  *Escherichia coli*         0.80 ± 0.00       0.16 ± 0.00    4.00 ± 0.00
  *Salmonella typhi*         0.16 ± 0.00       0.032 ± 0.00   20.00 ± 0.00
  *Shigella flexneri*        4.00 ± 0.00       0.16 ± 0.00    20.00 ± 0.00
  *Pseudomonas aeruginosa*   ---               0.80 ± 0.00    ---
  *Proteus mirabilis*        4.00 ± 0.00       0.80 ± 0.00    ---

Abbreviations: MIC, minimum inhibitory concentration; ---, no inhibitory effect starting from stock or first dilution.

MBC of the Leaf Extracts {#section17-2515690X19886276}
------------------------

The MBC cutoff points of Vo-80ME ranged from 0.8 mg/mL (against *S typhi*) to 20 mg/mL (*S aureus*, *S flexneri*, and *P mirabilis*). Relatively lower MBC values were recorded in Mc-80ME with the lowest MBC being 0.8 mg/mL (against strains of *E coli* and *S typhi*), whereas the maximum MBC recorded was 4.00 mg/mL against the remaining bacterial strains. In Me-80ME, however, the bactericidal effect was observed against *E coli* only, with MBC of 20 mg/mL. Generally, Mc-80ME killed the bacterial strains with relatively lower concentration and broader coverage ([Table 5](#table5-2515690X19886276){ref-type="table"}).

###### 

MBC (in mg/mL) of the Leaf Extract of *Verbena officinalis*, *Myrtus communis*, and *Melilotus elegans* Against Gram-Positive and Gram-Negative Bacteria.

![](10.1177_2515690X19886276-table5)

  Bacteria                   Plant Materials                 
  -------------------------- ----------------- ------------- --------------
  *Staphylococcus aureus*    20.00 ± 0.00      4.00 ± 0.00   ---
  *Escherichia coli*         4.00 ± 0.00       0.80 ± 0.00   20.00 ± 0.00
  *Salmonella typhi*         0.80 ± 0.00       0.80 ± 0.00   ---
  *Shigella flexneri*        20.00 ± 0.00      4.00 ± 0.00   ---
  *Pseudomonas aeruginosa*   ---               4.00 ± 0.00   ---
  *Proteus mirabilis*        20.00 ± 0.00      4.00 ± 0.00   ---

Abbreviation: ---, no bactericidal effect.

Discussion {#section18-2515690X19886276}
==========

Medicinal plants are increasingly targeted in the search for new antimicrobial agents.^[@bibr6-2515690X19886276],[@bibr41-2515690X19886276][@bibr42-2515690X19886276]--[@bibr43-2515690X19886276]^ In the 20th century, the primary sources of the present-day antimicrobials were microorganisms such as fungi and bacteria.^[@bibr44-2515690X19886276]^ In the 21st century, however, there is alarmingly increasing antimicrobial resistance on the available agents with very slow development of new antimicrobials.^[@bibr45-2515690X19886276],[@bibr46-2515690X19886276]^ Hence, we are facing a potential post-antibiotic era where the present-day agents are no longer effective.^[@bibr47-2515690X19886276],[@bibr48-2515690X19886276]^ It is, therefore, mandatory to extensively search for new agents based on the traditional use of herbal medicines as potential sources.

The use of and search for drugs derived from medicinal plants have accelerated in recent years. Ethnopharmacologists, botanists, microbiologists, and natural products chemists are searching worldwide for phytochemicals and "leads" that could be developed for treatment of infectious diseases. While around 50% of current pharmaceuticals are derived from plants origin, none are used as antimicrobials.^[@bibr6-2515690X19886276]^ Traditional healers have long used plants to prevent or cure infectious conditions. However, there is no sufficient scientific evidence to integrate the traditional system with modern medicine. To this end, plants are rich in a wide variety of secondary metabolites, such as tannins, terpenoids, alkaloids, and flavonoids, which have been found in vitro to have antimicrobial properties. Our finding has tried to provide a sort of scientific evidence for antibacterial activities of crude extracts of 3 medicinal plants having folkloric repute.

Based on this, the hydromethanolic extract of the leaves of *V officinalis* has shown a relatively moderate level of antibacterial activity against *S aureus*. Likewise, this plant extract is also endowed with secondary metabolites having antibacterial activity against a wide range of gram-negative pathogens. To this end, comparable level of activity was observed against *E coli* and *S typhi*, whereas poor antibacterial activity was recorded in *P aeruginosa* with the lowest concentration being totally devoid of any activity. *M elegans* is devoid of any antibacterial activity against *S aureus*, *P aeruginosa*, and *P mirabilis* in all tested concentrations. Nevertheless, this hydromethanolic extract exhibited appreciable antibacterial activity against standard strains of *E coli* and with mild to moderate zone of inhibition against *S typhi* and *S flexneri*.

The third medicinal plant is *M communis*, which is one of the most important medicinal plants that are being used in the Unani system of phytomedicine since ancient Greece period. Much has been investigated in the ethnobotany, ethnopharmacology, and phytochemistry of this plant in different parts of the world with high priority in Arabian countries.^[@bibr49-2515690X19886276][@bibr50-2515690X19886276][@bibr51-2515690X19886276][@bibr52-2515690X19886276]--[@bibr53-2515690X19886276]^ Though not conclusive, published reports indicated that the antibacterial activity of this plant material is broader in coverage with a remarkable activity.^[@bibr23-2515690X19886276],[@bibr28-2515690X19886276],[@bibr53-2515690X19886276]^ Indeed, the hydromethanolic extract of the leaves of *M communis* showed potent and concentration-dependent antibacterial activity against all tested gram-positive and gram-negative isolates. The remarkable activity of this plant extract against *S aureus* and *P aeruginosa* in particular put this agent as an important target for further purification and identification of bioactive constituents for treatment of infectious diseases.

The difference in antibacterial activity of these medicinal plants against different strains of bacteria is possibly attributable to the variation in the quality and quantity of bioactive secondary metabolites in the extracts of targeted morphological part (leaf). In line with this preliminary phytochemical screening, which showed the presence of terpenoids and flavonoids, previous phytochemical studies had reported the presence of iridoids (type of monoterpenoids), phenyl-propanoids, flavonoids, and terpenoids as the main components of *V officinalis.* More specifically, the hydroalcoholic and aqueous extracts were found rich in glucuronide-based flavonoids.^[@bibr12-2515690X19886276],[@bibr54-2515690X19886276]^ *M communis*, in particular, is very rich in secondary metabolites, notably supporting the high overall antibacterial activity from synergistic or additive interaction of these bioactive components. According to the preliminary phytochemical screening, *M elegans* is endowed with flavonoids and saponins as main secondary metabolites. Concordant with this, previously published reports revealed that flavonol glycosides, particularly kaempferol, were found as a major secondary metabolite.^[@bibr55-2515690X19886276]^ The reputed applications of *M elegans* leaves for the treatment of wounds, hemorrhoids, and other skin diseases in traditional medical practice seem to be well founded. As previous reports indicated, the activity of the plant is attributed to a combination of secondary metabolites, which belong to at least 3 classes of plant metabolites, namely, coumarins, flavonoids, and saponins. Based on this, the anti-inflammatory activity of this plant is well studied.^[@bibr12-2515690X19886276],[@bibr55-2515690X19886276],[@bibr56-2515690X19886276]^ However, the possible antibacterial activity was not evaluated before.

Being common secondary metabolites in 3 medicinal plants, efficacy and spectrum of antibacterial activity is probably due to, but not limited to, flavonoids. *M communis* is also rich in other secondary metabolites including terpenoids, tannins, saponins, and steroids, whereas *M elegans* contains saponins in addition to flavonoids. The antibacterial effects of *V officinalis* might be due to the combined effects of terpenoids and flavonoids detected in the leaf extract. Although it was found insufficient and unclear, a previous study conducted in 2 bacterial isolates (*S aureus* and *E coli*) indicated the high zone of inhibition and good MIC results of *V officinalis* against these pathogens without further analysis of MBC cutoff point.^[@bibr57-2515690X19886276]^ This study is expanded to address 1 gram-positive and 5 gram-negative bacteria with vivid MIC and MBC results for each. Apart from this, the poor antibacterial activity of *M elegans* might be due to the quality and quantity of its metabolites such as saponins and flavonoids in which the individual or combined antibacterial effect was found very modest. Several studies indicated that flavonoids, terpenoids, and tannins are secondary metabolites with high antibacterial potential, whereas saponins have little or no activity.^[@bibr58-2515690X19886276][@bibr59-2515690X19886276][@bibr60-2515690X19886276][@bibr61-2515690X19886276]--[@bibr62-2515690X19886276]^ This justification somehow supports the poor antibacterial activity of *M elegans*. Moreover, flavonoids and tannins have been shown to exhibit activity against Enterobacteriaceae including *E coli*, *P aeruginosa*, *K pneumonia*, and *P mirabilis.* ^[@bibr60-2515690X19886276][@bibr61-2515690X19886276]--[@bibr62-2515690X19886276]^ With regard to natural products, it is generally accepted that phytochemicals are less potent antibiotics than agents of microbial origin. However, new classes of antimicrobial drugs are urgently required and the flavonoids generally represent a novel set of leads for drug development. Future optimization of these compounds through structural modification (structure activity relationship) may allow the development of a pharmacologically acceptable antimicrobial agent or group of agents.^[@bibr63-2515690X19886276]^ Flavonoids have shown to inhibit a number of bacterial virulence factors, including quorum-sensing signal receptors, enzymes, and toxins. Evidence of these molecular effects at the cellular level includes in vitro inhibition of biofilm formation and inhibition of bacterial attachment to host ligands.^[@bibr61-2515690X19886276],[@bibr62-2515690X19886276]^

With the exception of *M communis* L, the rest plant extracts have shown poor or no activity against the difficult to treat gram-negative bacteria *P aeruginosa*. This might be due to the fact that this bacterium has outer membrane (porine channel) permeability problems coupled with efflux pump mechanisms.^[@bibr64-2515690X19886276][@bibr65-2515690X19886276]--[@bibr66-2515690X19886276]^ Besides, it allows highly polar constituents to pass through. Fortunately, the bioactive secondary metabolites of *M communis* possibly with expanded polarity reach to this target.

In line with the zone of inhibition, *M communis* has relativity good MIC results in all isolates tested. The MIC cutoff points of *V officinalis* ranges from 0.16 to 4.00 mg/mL. The higher MBC values than MIC cutoff points, recorded in all extracts, indicated the possibility of concentration-dependent bactericidal effects as observed in certain antibiotics such as aminoglycosides. *M elegans* has poor bactericidal activity against *E coli* only with the MBC value being 20 mg/mL.

All in all, this study has provided a starting point for further purification and isolation of active constituents with promising antibacterial activity. The extracts should be standardized for use in traditional medicine. Substantial efforts are needed to integrate the traditional medical systems with conventional medicine, a process that is currently at its infancy.

Conclusion {#section19-2515690X19886276}
==========

The study attempted to validate the potential antibacterial activity of medicinal plants having folkloric repute in Ethiopian traditional medicine. Accordingly, the leaf extract of *M communis* showed remarkable zone of inhibitions in all tested bacterial isolates including *P aeruginosa*. Besides, *V officinalis* showed good antibacterial activity against *S aureus*, *E coli*, and *S typhi*, indicating the broader spectrum of activity. Nevertheless, *M elegans* has shown good activity against *E coli* with little or no activity to the rest of the isolates. Generally, *M communis* and *V officinalis* have good MIC and MBC results. The higher MBC value indicates the concentration-dependent bactericidal effect of extracts. The difference in the antibacterial activity of these medicinal plants is possibly due to the variation in the quality and quantity of bioactive phytoconstituents.

Strength and Limitations {#section20-2515690X19886276}
========================

Even though this study has evaluated the antibacterial activity of 3 medicinal plants against a wide range of microorganisms with vivid MIC and MBC cutoff points, it is limited to the standard isolates of ATCC because the ultimate purpose of this study was to confirm antibacterial activity but not to test susceptibility.
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